BeOne’s next-gen BCL2 inhibitor wins FDA approval, taking aim at Venclexta

May 14, 2026 06:31 AM EDTUpdated 10:53 AM PharmaFDA+ Up­dat­ed: BeOne’s next-gen BCL2 in­hibitor wins FDA ap­proval, tak­ing aim at Ven­clex­ta Ayisha Sharma News Reporter BeOne Med­i­cines has clinched US ac­cel­er­at­ed ap­proval for its drug son­ro­to­clax in man­tle cell lym­phoma (MCL), mark­ing the start of its bid to chal­lenge Ab­b­Vie … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER